...
首页> 外文期刊>Journal of Thoracic Disease >Gender differences in aortic valve replacement: is surgical aortic valve replacement riskier and transcatheter aortic valve replacement safer in women than in men?
【24h】

Gender differences in aortic valve replacement: is surgical aortic valve replacement riskier and transcatheter aortic valve replacement safer in women than in men?

机译:主动脉瓣置换的性别差异:外科主动脉瓣更换风险和经膜状管主动脉瓣更换女性比男性更安全吗?

获取原文

摘要

Aortic stenosis (AS) is a progressive and degenerative disease that necessitates valve replacement through either surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). Various studies have shown that, unlike for TAVR, SAVR is associated with an elevated risk for women as compared to men. The aim of this review is to better understand the risks and their possible causes, associated with the use of both TAVR and SAVR in female patients. Our systematic review included studies published between 2012 and 2020, identified through specific searches of PubMed. Compatibility of publications, determined by the use of pre-defined inclusion/exclusion criteria, resulted in 15 articles being used in our review. Overall, more men than women undergo SAVR, but our findings confirmed that SAVR is associated with worse outcomes in women in the short-term. Reasons for a higher 30-day mortality post-SAVR in women include an increased age, higher in-hospital mortality and, possibly baseline comorbidities and anatomical differences. There was no difference observed in 30-day mortality between men and women undergoing TAVR. Female patients appear to have a better longer-term survival post-TAVR than their male counterparts. Understanding the reasons why women have worse outcomes post-SAVR is essential for ensuring appropriate treatment selection for patients with AS, as well as for achieving the best possible long-term and safety outcomes for these patients.
机译:主动脉狭窄(AS)是一种渐进性和退行性疾病,需要通过手术主动脉瓣置换(SAVR)或经膜状管主动脉瓣更换(TAVR)来置换瓣膜。各种研究表明,与TAVR不同,萨维尔与男性相比,萨姆率与女性的危险升高。本综述的目的是更好地了解与女性患者中TAVR和SAVR的使用相关的风险及其可能的原因。我们的系统评价包括2012年和2020年之间发布的研究,通过特定搜索Pubmed搜索。通过使用预定义的包含/排除标准确定出版物的兼容性,导致我们审查中使用了15篇文章。总体而言,比女性更多的男性经历Savr,但我们的调查结果证实,Savr在短期内与女性更糟糕的结果有关。女性遗产30天死亡率提高的原因包括增加年龄,患儿高度的死亡率,并且可能是基线合并症和解剖学差异。在接受TAVR的男性和女性之间的30天死亡率中没有差异。女性患者似乎具有比男性同行的更好的长期生存。了解妇女更糟糕的结果的原因,萨维尔后期对确保患者的适当治疗选择是必不可少的,以及实现这些患者的最佳长期和安全结果的适当治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号